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Abstract 
 
Objectives.  Invasive liver biopsy is the current method for the assessment of liver 
fibrosis. In search of non-invasive alternatives, galectin-3-binding protein was 
introduced as a candidate-marker of hepatitis C-related fibrosis based on serum 
proteomics. 
We investigated the role of galectin-3-binding protein as a single-marker of 
significant fibrosis and cirrhosis by means of serology and histology and studied the 
role of glycosylation on the expression in hepatitis C- and alcohol-related cirrhosis. 
Methods. Sera and available biopsies of hepatitis C patients with various fibrosis-grades 
and patients with alcohol-related cirrhosis were used for galectin-3-binding protein 
measurements by enzyme-linked immunosorbent assay and immunohistochemistry, 
respectively. Glycosylation-effect was analyzed by Western blot. Data was analyzed in 
accordance to fibrosis.  
Results. Galectin-3-binding protein was increased during cirrhosis (22.7 ± 10.1 µg/mL) 
in contrast to mild (11.3 ± 6.4 µg/mL) and moderate fibrosis (13.4 ± 8.3 µg/mL) (p < 
0.001; p = 0.004, respectively). Receiver operator characteristics curves showed areas 
under the curve of 0.68 and 0.81 for the detection of respectively significant fibrosis and 
cirrhosis. Similar findings in hepatic expression were obtained, in which cirrhosis was 
associated with diffuse, parenchymal expression (p = 0.002). The observed difference 
between hepatitis C- and alcohol-related cirrhosis (13.5 ± 9.0 µg/mL) (p = 0.009) could 
not be explained by glycosylation. (mean ± standard deviation) 
Conclusions. Our recent findings confirm our initial proteome results on serological 
and histological level as well as the role of galectin-3-binding protein as a marker of 
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hepatitis C-related fibrosis, especially cirrhosis. Implication of this protein in future 
multi-marker study should be considered. 
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1. Introduction 
 
Hepatitis C viral infection is one of the major chronic liver diseases with an estimated 
prevalence of 3%, about 170 million cases worldwide [1, 2]. Chronic hepatitis C 
patients are prone to develop liver fibrosis and cirrhosis, characterized by an excessive 
accumulation of extracellular matrix proteins within the liver [3, 4]. Liver fibrosis is a 
slow and factor-dependent (i.e. alcohol, age, gender) process and it is therefore essential 
to closely monitor the fibrosis-progression in order to initialize an appropriate antiviral 
treatment [3, 5, 6]. Liver biopsy with subsequent histological examination is the current 
diagnostic standard for fibrosis assessment, but is limited due to invasiveness and 
potential sampling error; this has stimulated the search for non-invasive alternatives [7-
10]. 
In this regard, we previously analyzed the serum proteome of chronic hepatitis C 
patients in search of new protein-markers of fibrosis by means of two-dimensional gel 
electrophoresis and mass spectrometry; Among the identified proteins, galectin-3-
binding protein was shown to be specifically up-regulated in advanced stages of 
fibrosis, especially cirrhosis [11]. Galectin-3-binding protein is a secreted 90 kDa N-
glycosylated protein with affinity for galectins as well as extracellular matrix proteins 
[12]. Sudden increase in serum galectin-3-binding protein levels have been reported in 
various infectious and cancerous diseases, including hepatitis C [13-22]. 
In the present study, we investigated the role of galectin-3-binding protein as a 
single-marker of hepatitis C-related fibrosis by means of serological and histological 
assessment of hepatitis C patients. Furthermore, we investigated the role of 
glycosylation in the difference of serum galectin-3-binding protein expression in 
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hepatitis C- and alcohol-related cirrhosis [17, 23]. We chose cirrhosis for this 
comparison due to substantial difference in fibrogenesis and pathological scoring 
systems in pre-cirrhotic stages [24]. 
 
 
2. Methods 
 
2.1. Study population 
This mono-centric study consisted of chronic hepatitis C patients (n = 76), alcohol-
related cirrhotic patients (n = 11) and controls (n = 5), registered at the Department 
of Gastroenterology and Hepatology at Ghent University Hospital (Ghent, 
Belgium). All patients gave informed consent prior to the start of the study. The 
study was also approved by the Ethical Committee of the Ghent University Hospital. 
Viral status was confirmed by anti-HCV enzyme immunoassay (EIA), HCV 
RNA-PCR, while fibrosis-grade (F0 = no fibrosis; F1 = portal fibrosis without 
septa; F2 = portal fibrosis with few septa; F3 = numerous septa without cirrhosis; F4 
= cirrhosis) and inflammatory activity (A0 = no activity; A1 = mild activity; A2 = 
moderate activity; A3 = severe activity) were assessed by liver biopsy according to 
the Metavir scoring-system [25, 26]. 
All patient’s sera were stored at -20 °C at the Department of Gastroenterology 
and Hepatology, while available tissue specimens of chronic hepatitis C patients (n 
= 20) were obtained from the Department of Pathology at Ghent University Hospital 
(Ghent, Belgium). Patients with anti-viral treatment, co-infection, severe 
decompensation according to the Child-Pugh score (> score A) (bilirubin > 2 
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mg/dL, albumin < 3.5 mg/dL, international normalized ratio > 1.7, ascites and 
encephalopathy) or hepatocellular carcinoma (HCC) were excluded from the study. 
 
2.2. Serum galectin-3-binding protein measurement 
Serum galectin-3-binding protein levels were measured by means of a commercially 
available enzyme-linked immunosorbent assay (ELISA) (BMS234, Bender 
MedSystems®, Vienna, Austria). Briefly, patient’s sera were diluted and loaded onto 
a monoclonal antibody-coated 96-microwell plate. The plate was incubated at 37 °C 
for 45 min, subsequently washed and re-incubated with a second monoclonal horse 
radish peroxidase (HRP-) labeled antibody at 37 °C for 45 min. After repeating the 
washing procedure, tetramethylbenzidine (TMB) substrate solution was added to the 
wells and incubated at room temperature for 15 min while shaking at 100 rpm. 
Substrate reaction was stopped after addition of an acid-based stop solution. 
Absorbance was measured and analyzed by UV-VIS spectrophotometry (Safire², 
Tecan, Männedorf, Switzerland) at 450 nm; serum galectin-3-binding protein levels 
were determined by plotting the standard curve. The intra- and inter-assay 
coefficients of variation were 5.5 and 11.9%, respectively, according to user’s 
manual.  
 
2.3. Galectin-3-binding protein immunohistochemistry 
Paraffin-embedded sections (5 µm) were dewaxed in an iso-paraffin based clearing 
agent (UltraClear®, Klinipath, Geel, Belgium) and rehydrated in graded ethanol 
baths (99% and 96%) (Klinipath). Antigen retrieval was performed with citrate 
buffer, containing 10 mM sodium citrate (pH 6) (Sigma-Aldrich, Steinheim, 
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Germany) and 0.05% Tween-20 (MP Biomedicals, Solon, OH, USA) at 95 °C for 
20 min. Non-specific sites on the slides were blocked with phosphate buffer saline 
(PBS) (pH 7.4) (Invitrogen, Grand Island, NY, USA) containing 1% (w/v) bovine 
serum albumin (BSA) (Sigma-Aldrich) and 0.3% (v/v) Triton-X (Sigma-Aldrich) 
for 10 min. Subsequently, tissue sections were incubated with primary antibody 
(1:200) (R&D Systems, Oxfordshire, UK) overnight at 4 °C. Endogenous 
peroxidase-activity was blocked with PBS (pH 7.4) (Invitrogen) containing 3% (v/v) 
H2O2 and 1% (w/v) sodiumazide (NaN3) (Sigma-Aldrich) at room temperature for 
20 min. After subsequent incubation in biotinylated secondary antibody and 
streptavidin-HRP (LSAB + system-HRP, Dako, Carpinteria, CA, USA), galectin-3-
binding protein expression was visualized by diaminobenzidine (DAB) (DAB 
Substrate-Chromogen System, Dako) and haematoxylin-mayer (J.T. Baker, 
Deventer, Holland). Sections were eventually dehydrated in 96% and 99% ethanol 
(Klinipath) and iso-paraffine based solution (Klinipath). Primary antibody was 
replaced by normal goat immunoglobulin G (1:100) (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) as negative control. 
Staining intensity was blindly assessed by a single pathologist (L.L.) without 
previous knowledge of the patient’s condition at the moment of scoring. Protein 
stain in the liver parenchyma was either absent (0), centrolobular (1) or panlobular 
(3) [14]. 
 
2.4. Deglycosylation of serum galectin-3-binding protein 
Galectin-3-binding protein has about 7 N-glycosylation sites, which have substantial 
influence on antibody affinity; moreover, it is known that serum glycoproteins are 
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altered in alcoholic and cirrhotic patients [23, 27, 28]. In this regard, the role of N-
glycans in serum galectin-3-binding protein expression was studied by comparison 
of deglycosylated galectin-3-binding protein expression in hepatitis C- and alcohol-
related cirrhosis. 
Denatured serum proteins (1 µg/µL) was prepared by sample dilution in 20 mM 
ammoniumbicarbonate (pH 8.0) (Sigma-Aldrich) and subsequent denaturation in 
0.2% sodium dodecyl sulphate (SDS) (MP Biomedicals) an d 1 0  mM β-
mercaptoethanol (Sigma-Aldrich) at 100 °C for 10 min. 1 µL peptide:N-glycosidase 
F (0.5 IUB mU PNGaseF) (Sigma-Aldrich) was added to the samples and incubated 
at 37 °C for 3 hrs. The enzymatic reaction was stopped by heating up to 95 °C for 5 
min in non-reducing sample buffer (Thermo Scientific, Rockford, IL, USA) with 
5% β-mercaptoethanol (Sigma-Aldrich). Simultaneously, raw serum proteins (15 
µg) were reduced in Laemmli-buffer at 95 °C for 5 min. Laemmli-buffer contained 
50 mM TrisHCl (pH 6.8) (MP Biomedicals), 2% (w/v) SDS (MP Biomedicals), 3 M 
urea (Sigma-Aldrich), 10% (v/v) glycerol (MP Biomedicals) and 5% (v/v) β-
mercaptoethanol (Sigma-Aldrich). Samples were resolved on a 10% SDS-
polyacrylamide gel in an electrophoresis cell (CriterionTM Cell, Bio-Rad, Hercules, 
CA, USA) at 150 V and 200 V for 30 min and 1 hr 30 min, respectively. The 
resolving gel contained 40% acrylamide:bisacrylamide (29:1) (Bio-Rad), 1.5 
TrisHCl (pH 8.8) (MP Biomedicals), 10% (w/v) SDS (MP Biomedicals), 10% (w/v) 
ammonium persulphate (Sigma-Aldrich) and 0.05% (v/v) TEMED (Sigma-Aldrich). 
Running buffer contained 2.5 mM Tris (MP Biomedicals), 0.1% (w/v) SDS (MP 
Biomedicals) and 192 mM glycine (Fisher Scientific, Fair Lawn, NJ, USA). Protein 
transfer onto the nitrocellulose membrane was performed by tank-blotting (Trans-
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Blot® Electrophoretic Transfer Cell, Bio-Rad) containing transfer solution at 110 V 
for 90 min. Transfer solution contained 48 mM Tris (MP Biomedicals), 39 mM 
glycine (Fisher Scientific), 20% (v/v) methanol (VWR International, Leuven, 
Belgium). 
Protein transfer and loading were checked using 0.1% (w/v) Ponceau-S (Sigma-
Aldrich) in 5% (v/v) acetic acid (Merck, Hohenbrunn, Germany). Next, the blot was 
blocked with PBS (pH 7.4) (Invitrogen) containing 1% (w/v) BSA (Sigma-Aldrich) 
and 0.1% (v/v) Tween-20 (MP Biomedicals) for 1 hr. Subsequently, the blot was 
incubated with primary antibody (1:400) (R&D Systems) overnight at 4 °C. The blot 
was washed and incubated with a secondary HRP-labelled bovine anti-goat antibody 
(1:10000) (Santa Cruz Biotechnology) for 1 hr. After repeating the wash steps, 
primary antibody was detected by chemiluminiscence using luminol/H2O2 
(SuperSignal® West Dura, Thermo Scientific) and imaging System (Versadoc, Bio-
Rad). Protein band patterns were analyzed using appropriate sofware (Quantity One, 
Bio-Rad). 
 
2.5. Statistical analysis.  
Fibrosis-grades according to the Metavir scoring-system was regrouped into three 
consecutive stages: mild fibrosis (F0 – F1), moderate fibrosis (F2 – F3) and 
cirrhosis (F4). Inflammatory activity-grading was regrouped into two stages: mild 
activity (A0 – A1) and significant activity (A2 – A3). Genotypes were regrouped 
into genotype 1 – 4, 2 – 3 and others according to previous findings, suggesting a 
more prominent increase of serum galectin-3-binding protein in genotype 1 and 4  
[13, 14, 16, 19]. 
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Continuous data and categorical/nominal data were analyzed in accordance with 
fibrosis-grades by means of respectively analysis of variances (ANOVA) and 
Fisher’s exact test. Data was log-transformed if appropriate.  
 Receiver operator characteristic (ROC) curves and area under the curve (± 
standard error; 95% confidence interval) were calculated in order to evaluate the 
performance of serum galectin-3-binding protein as single-marker in the detection 
of significant fibrosis (≤ F2) and cirrhosis (F4). Statistical analyses were performed 
in SPSS v.15.0 (SPSS, Chicago, IL, USA) and R v.2.8.1 (R-software). A p-value < 
0.05 was considered statistically significant. 
 
 
3. Results 
 
3.1. Serum galectin-3-binding protein 
Serum galectin-3-binding protein expression was associated with hepatitis C-related 
fibrosis-grades (p < 0.001), similar to age at sampling and albumin amount (Table 
1). Post-hoc analysis even showed an increase during cirrhosis (F4) (22.7 ± 10.1 
µg/mL) in contrast to pre-cirrhotic stages (F0 – F1, F2 – F3) (p < 0.001 and p = 
0.004, respectively). Despite significant distinction between fibrosis-grades, 
albumin-, bilirubin- and INR-values did not drastically exceed normal reference-
values (Table 1). 
 ROC-curves showed that serum galectin-3-binding protein has an area under the 
curve of 0.68 (± 0.06; [0.56 – 0.80]) and 0.81 (± 0.06; [0.69 – 0.91]) for the 
detection of respectively significant fibrosis (≥ F2) and cirrho sis (F4) (Figure 1). 
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Serum levels above 12.9 µg/mL have a sensitivity of 0.60 and specificity of 0.65 for 
the diagnosis of significant fibrosis; while levels above 16.9 µg/mL have a 
sensitivity of 0.70 and specificity of 0.75 for the diagnosis of cirrhosis (Figure 1). 
 
3.2. Hepatic galectin-3-binding protein 
Immunohistochemistry of hepatitis C-related specimens showed positive, granular 
staining within cytoplasm of hepatocytes and occasional staining of reactive bile 
ductules and bile canaliculi (Figure 2). 
 Statistical outcomes of the biopsy-population were strongly similar to the total 
hepatitis C population of this mono-centric study (Table 2). Positive hepatocellular 
expression was shown to be correlated with fibrosis-grades and steatosis (p = 0.002; 
p = 0.007, respectively) and was independent of patient’s gender, viral genotype and 
inflammatory activity. Analysis of the histological expression in association with 
fibrosis-grade resulted in the following characteristics:  
F0 – F1 was characterized by weak and moderate, centrolobular expression, F2 – 
F3 was characterized by moderate, centrilobular and diffuse, panlobular expression, 
while F4 was associated with diffuse, panlobular expression (Figure 2). The 
difference in histological expression between fibrosis-grades was significant 
between F0 – F1 and F4 following post-hoc analysis (p < 0.05). 
 Moreover, serum galectin-3-binding protein levels and immunohistochemistry 
were significantly associated with each other (p = 0.038); diffuse, panlobular 
expression was associated with a mean galectin-3-binding protein concentration of 
25.1 (± 9.9) µg/mL. 
 
  
13 
13 
3.3. Hepatitis C- opposite alcohol-related cirrhosis 
In general, cirrhosis is similar in all chronic liver diseases being characterized by an 
overall loss of normal liver structure due to regenerative nodule-formation. In 
addition, histological expression in alcoholic liver specimen has shown a similar 
diffuse staining pattern (Figure 2). 
Both pathologies showed a significant increase in contrast to healthy controls 
(3.2 ± 1.3 µg/mL) (p < 0.001); serum galectin-3-binding protein levels were 13.5 (± 
9.0) µg/mL and 22.7 (± 10.1) µg/mL for respectively alcohol- and hepatitis C-
related cirrhosis (Figure 3). Moreover, serum levels in hepatitis C-related cirrhosis 
were more elevated than in alcoholic cirrhosis (p = 0.009). Alcoholic patients were 
not severely decompensated at the time of sampling (data not shown). 
In order to investigate whether glycosylation is involved in this observed 
discrepancy, a qualitative study of deglycosylated galectin-3-binding protein was 
conducted by means of Western blotting. Untreated serum galectin-3-binding 
protein band was observed at ±100 kDa following Western blot, while 
deglycosylation resulted in two minor bands at 60 kDa due to the loss of all N-
glycans (Figure 3). No difference was detected in band expression of untreated and 
deglycosylated galectin-3-binding protein between both aetiologies. 
 
 
Discussion 
 
Non-invasive assessment of liver fibrosis in chronic hepatitis C (CHC) patients has 
evolved rapidly in the past ten years due to new pathological insights and technologies; 
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diagnostic techniques, such as the Fibroscan, have already been implemented into daily 
practice [29, 30]. Technological progress also enables new ways to discover useful 
disease markers (i.e. proteomics, glycomics) [11, 31-33]. Our previous serum proteome 
study in hepatitis C patients identified galectin-3-binding protein as marker of advanced 
fibrosis, especially cirrhosis [11]. 
In the current study, we investigated the role of this protein as a single-marker of 
significant hepatitis C-related fibrosis and cirrhosis by means of serological and 
histological testing. Serum measurement and subsequent univariate analysis confirmed 
our previous proteome findings by detecting a gradual increase in protein level towards 
end-stage liver disease. Like most single-marker studies, clear distinction was observed 
between the two most extreme stages (F0 – F1 and F4) with substantial overlap between 
the other stages. Serum galectin-3-binding protein showed a good diagnostic 
performance for the detection of cirrhosis, in which optimal sensitivity and specificity 
were similar for the respectively detection and exclusion of cirrhosis (about 0.70). 
In contrast to many previous marker reports, we confirmed our proteome findings 
by detecting galectin-3-binding protein within liver tissue of chronic hepatitis C patients 
with varying fibrosis-grades. Moreover, despite the limited sample size, we were able to 
confirm a same increase in protein-level at hepatic tissue level. A clear distinction in 
hepatocellular expression was observed between mild fibrosis (F0 – F1) and cirrhosis 
(F4), which was characterized by a clear zonular expression in centro- and panlobular 
areas. Serological and histological outcome were even positively correlated following 
association-studies. The expression of galectin-3-binding protein was also accompanied 
by hepatic steatosis, a common feature of chronic hepatitis C; previous reports have 
associated steatosis with fibrosis progression and severity [34-39].  
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Besides hepatocellular expression, occasional galectin-3-binding protein staining 
was detected in reactive bile ductules and canaculi, which has not been previously 
reported. Bile ductular reaction is known to increase during hepatitis C-related cirrhosis 
development due to bile ductular metaplasia [40, 41]; this might imply a potential role 
for galectin-3-binding protein in very early stages of neoplasia or abnormal cellular 
manifestations. Galectin-3-binding protein has already been associated with the bile 
proteome as well as biliary tract carcinoma [20, 42]. On the other hand, detection in 
canaliculi confirms an active protein secretion by hepatocytes into the extracellular 
space. 
Difference in serum levels of galectin-3-binding protein in cirrhotic patients due to 
etiology has previously been observed [17]; in this regard, we investigated whether 
post-translational glycosylation has an intrinsic effect on protein expression in hepatitis 
C- and alcohol-related cirrhosis. However, this was not the case, suggesting a more in 
vivo alteration in gene or protein regulation due to difference in molecular pathway [3, 
4, 43-47]. Evidence of these alterations in hepatitis C has been provided by Bigger et 
al., reporting a change in hepatic gene regulation during course and clearance of viral 
hepatitis C in primates [48]. Also, previous studies have associated increased serum 
galectin-3-binding protein levels with viral genotype 1 - 4 [13, 14, 16, 19].  According 
to these findings, galectin-3-binding protein is likely a hepatitis C-specific marker of 
fibrosis rather than a universal fibrosis marker, despite significant increase in protein-
level in both pathologies. 
Galectin-3-binding protein is believed to have immuno-, cytokine modulating 
properties, but the actual functional role in viral hepatitis C and liver fibrosis remains 
unclear [49, 50]. On the other hand, galectin-3 has been associated with active 
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regulation of fibrosis [51, 52]. The absence of galectin-3-binding protein stain at the 
actual fibrotic lesions as well as lack of correlation with inflammation in our study, 
suggest a possible indirect involvement in hepatitis C-related liver fibrosis [53].  In 
addition, the increase in protein levels in sera and tissue could also be an indication of 
early neoplastic events [17, 20]. 
In conclusion, we provided confirmation of our proteome study and substantial 
evidence that galectin-3-binding protein expression is representative for the progressive, 
aggravating events of the liver following viral hepatitis C at a serological as well as 
histological level. At a single-marker level serum galectin-3-binding protein shows 
potential as an indicator of compensated cirrhosis; it might therefore be interesting to 
integrate this serum protein in a multi-marker test for the detection of hepatitis C-related 
liver fibrosis. Our results warrant the comparison of the accuracy of this marker with 
that of other proposed non-invasive markers of fibrosis [54-57]. 
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Table 1. Hepatitis C patient’s characteristics (n = 76). 
 Valid cases* 
F0 – F1 
(n = 26) 
F2 – F3 
(n = 27) 
F4 
(n = 23) 
p-value† 
Gender (male/female) 100% 14/12 15/12 15/8 0.71 
Genotype (1-4/2-3/other) 93% 16/5/3 21/4/1 18/3/0 0.50 
Activity (A0-A1/A2-A3) 83% 23/1 15/12 6/6 < 0.001 
Age (years) 100% 
39.7 
(± 13.1) 
50.6 
(± 14.7) 
58.0 
(± 11.0) 
< 0.001 
BMI (kg/m²) 80% 
24.0 
(± 3.8) 
25.0 
(± 4.4) 
26.6 
(± 3.2) 
0.11 
G3BP (µg/mL)‡ 100% 
11.3 
(± 6.4) 
13.4 
(± 8.3) 
22.7 
(± 10.0) 
< 0.001 
Albumin  
(3.4 – 4.8 g/dL) 
99% 
4.6 
(± 0.3) 
4.5 
(± 0.3) 
4.0 
(± 0.3) 
< 0.001 
Bilirubin  
(0.3 – 1.2 mg/dL)‡ 
99% 
0.7 
(± 0.5) 
0.7 
(± 0.4) 
1.1 
(± 0.9) 
0.006 
INR 
(0.9 – 1.3) 
99% 
1.0 
(± 0.1) 
1.0 
(± 0.1) 
1.3 
(± 0.1) 
0.02 
Body mass index (BMI), galectin-3-binding protein (G3BP), International normalized 
ratio (INR). 
*Valid cases represent the percentage of available data. 
Numeric data is represented in mean (± standard deviation) and categorical/nominal 
data in counts. 
†parameters were analyzed in accordance with fibrosis-grades by means of univariate 
analysis of variances (ANOVA) and Fisher’s exact test for respectively continuous and 
categorical/nominal data.  
‡Statistiscal analysis conducted on log-transformed data. 
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Table 2. Hepatitis C patient’s characteristics of the liver biopsies (n = 20). 
 Valid cases* 
F0 – F1 
(n = 7) 
F2 – F3 
(n = 9) 
F4 
(n = 4) 
p-value† 
Gender (male/female) 100% ¾ 4/5 3/1 0.71 
Genotype (1-4/2-3/other) 95% 6/0/0 8/0/1 3/1/0 0.47 
Activity (A0-A1/A2-A3) 83% 7/0 3/6 2/2 0.02 
Steatosis (absent/present) 100% 7/0 5/4 0/4 0.003 
G3BP (E1/E2/E3)* 100% 3/0/0 4/6/0 0/3/4 0.002 
Age (years) 100% 
32.9 
(± 14.4) 
54.4 
(± 14.5) 
45.3 
(± 12.7) 
0.03 
BMI (kg/m²) 80% 
24.2 
(± 3.8) 
26.4 
(± 5.0) 
27.9 
(± 2.3) 
0.43 
Albumin 
 (3.4 – 4.8 g/dL) 
99% 
4.7 
(± 0.1) 
4.4 
(± 0.2) 
4.0 
(± 0.3) 
0.001 
Bilirubin  
(0.3 – 1.2 mg/dL)‡ 
99% 
0.9 
(± 0.9) 
0.7 
(± 0.4) 
1.4 
(± 1.5) 
0.64 
INR 
(0.9 – 1.1) 
99% 
1.0 
(± 0.1) 
1.0 
(± 0.1) 
1.2 
(± 0.2) 
0.04 
Body mass index (BMI), galectin-3-binding protein (G3BP), International normalized 
ratio (INR), expression-pattern (E): weak (E1), moderate (E2) and diffuse (E3). 
*Valid cases represent the percentage of available data. 
Numeric data is represented in mean (± standard deviation) and categorical/nominal 
data in counts. 
†parameters were analyzed in accordance with fibrosis-grades by means of univariate 
analysis of variances (ANOVA) and Fisher’s exact test for respectively continuous and 
categorical/nominal data.  
‡Statistiscal analysis conducted on log-transformed data. 
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 Figure legends 
 
Figure 1. Receiver operator characteristic (ROC) curves with corresponding area under 
the curve-values (0.68 and 0.81) of serum galectin-3-binding protein for the detection of 
respectively significant fibrosis (≥ F2) (a) and cirrhosis (F4) (b). Dot -plot (c) shows the 
individual serum measurements of galectin-3-binding protein: cut-off value at 12.9 
µg/mL (full line), galectin-3-binding protein has sensitivity of 0.60 and specificity of 
0.65 in the detection of significant fibrosis (≥ F2); while cut -off value at 16.9 µg/mL 
(dashed line), galectin-3-binding protein has a sensitivity of 0.70 and specificity of 0.75 
for the detection of cirrhosis (F4). 
 
Figure 2. Galectin-3-binding protein expression in hepatitis C-related (a – c) (20x 
magnification) and alcoholic cirrhosis (d) (40x magnification) by means of 
immunohistochemistry and haematoxylin background-staining. Positive immuno-stain 
was represented by a brown-like stain within cytoplasm of the hepatocytes (a – d), while 
negative staining was represented by a blue-like stain, seen in the negative control 
(n.c.). Three different positive staining-patterns could be distinguished: no or rare 
positive hepatocytes (a); cytoplasmic positivity in the centrolobular hepatocytes (b); 
diffuse, panlobular staining of the parenchyma (c). In addition, occasional staining of 
reactive bile ductules (BD) and caniculi (CA) were detected (d).  Vascular structures (a) 
(black arrow) and mononuclear infiltrates (c) (white arrow) were negatively stained. 
Central vein (CV) and portal tract (PT) (b). 
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Figure 3. Serum galectin-3-binding protein levels in healthy controls, hepatitis C-
related and alcoholic cirrhosis by means of enzyme-linked immunosorbent assay 
(ELISA) (a) and Western blot (b). (a) Increase in serum levels was observed in cirrhotic 
patients in contrast to healthy controls (p < 0.001); moreover, serum levels in hepatitis 
C-related cirrhosis were more elevated in contrast to alcoholic cirrhosis (p = 0.009). 
error bar graph represent mean-values with bars representing standard error of the mean. 
(b) protein bands were detected at ± 100 kDa (raw) (3 and 5) and ± 60 kDa 
(deglycosylated) (4 and 6). The minor bands (arrows) after deglycosylation showed no 
significant difference in expression or pattern between alcohol- and hepatitis C-related 
cirrhosis. Galectin-3-binding protein in the healthy control (lane 1 and 2) was below 
detection limit. 
